Qi Y, Deng S, Wang K
Am J Cancer Res. 2024; 14(9):4172-4196.
PMID: 39417188
PMC: 11477839.
DOI: 10.62347/KIVS3169.
Adamczewska-Wawrzynowicz K, Wiacek A, Kozlowska A, Mikosza K, Szefler L, Dudlik W
Discov Oncol. 2023; 14(1):98.
PMID: 37314524
PMC: 10267092.
DOI: 10.1007/s12672-023-00658-7.
Hebron K, Wan X, Roth J, Liewehr D, Sealover N, Frye W
Clin Cancer Res. 2022; 29(2):472-487.
PMID: 36322002
PMC: 9852065.
DOI: 10.1158/1078-0432.CCR-22-1646.
Lin S, Lin C, Lee W, Teng C, Shyu W, Jeng L
Int J Mol Sci. 2022; 23(19).
PMID: 36233084
PMC: 9570316.
DOI: 10.3390/ijms231911781.
Ma G, Tan C, Shan Y, Shao N, Wang F, Dimitrov D
J Cancer. 2022; 13(6):1830-1836.
PMID: 35399718
PMC: 8990425.
DOI: 10.7150/jca.69064.
Insuline-Like Growth Factor-2 (IGF2) and Hepatocyte Growth Factor (HGF) Promote Lymphomagenesis in p53-null Mice in Tissue-specific and Estrogen-signaling Dependent Manners.
Huang H, Chu S, Chen P, Lee M, Huang C, Chou H
J Cancer. 2021; 12(20):6021-6030.
PMID: 34539876
PMC: 8425200.
DOI: 10.7150/jca.60120.
IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients.
Vewinger N, Huprich S, Seidmann L, Russo A, Alt F, Bender H
Int J Mol Sci. 2019; 20(12).
PMID: 31234291
PMC: 6627083.
DOI: 10.3390/ijms20123027.
Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeutics.
Pal A, Chiu H, Taneja R
Redox Biol. 2019; 25:101124.
PMID: 30709791
PMC: 6859585.
DOI: 10.1016/j.redox.2019.101124.
Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L, Pandya P, Liu E, Chandra P, Wang L, Murray M
BMC Med Genomics. 2019; 12(Suppl 1):23.
PMID: 30704460
PMC: 6357363.
DOI: 10.1186/s12920-018-0456-5.
Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
Li T, Wang J, Liu P, Chi J, Yan H, Lei L
Oncotarget. 2017; 8(29):47269-47283.
PMID: 28521298
PMC: 5564563.
DOI: 10.18632/oncotarget.17617.
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder B, Yohe M, Chou H, Zhang X, Marques J, Wachtel M
Cancer Discov. 2017; 7(8):884-899.
PMID: 28446439
PMC: 7802885.
DOI: 10.1158/2159-8290.CD-16-1297.
Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus.
Yan Y, Hu F, Wu W, Ma R, Huang H
Medicine (Baltimore). 2017; 96(12):e6393.
PMID: 28328831
PMC: 5371468.
DOI: 10.1097/MD.0000000000006393.
CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.
Manara M, Terracciano M, Mancarella C, Sciandra M, Guerzoni C, Pasello M
Oncotarget. 2016; 7(48):79925-79942.
PMID: 27835596
PMC: 5346761.
DOI: 10.18632/oncotarget.13160.
Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.
Denduluri S, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed M
Genes Dis. 2015; 2(1):13-25.
PMID: 25984556
PMC: 4431759.
DOI: 10.1016/j.gendis.2014.10.004.
IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X, Yeung C, Heske C, Mendoza A, Helman L
Neoplasia. 2015; 17(4):358-66.
PMID: 25925378
PMC: 4415145.
DOI: 10.1016/j.neo.2015.03.001.
A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.
Zhao Q, Tran H, Dimitrov D, Cheung N
Int J Cancer. 2015; 137(9):2243-52.
PMID: 25924852
PMC: 4978514.
DOI: 10.1002/ijc.29588.
Insulin-like growth factor system in cancer: novel targeted therapies.
Brahmkhatri V, Prasanna C, Atreya H
Biomed Res Int. 2015; 2015():538019.
PMID: 25866791
PMC: 4383470.
DOI: 10.1155/2015/538019.
Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.
Reimann E, Koks S, Ho X, Maasalu K, Martson A
Hum Genomics. 2014; 8:20.
PMID: 25496518
PMC: 4272536.
DOI: 10.1186/s40246-014-0020-0.
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M, Perentesis J, Wagner L, Vinks A, Reid J, Ahern C
Clin Cancer Res. 2014; 21(7):1558-65.
PMID: 25467181
PMC: 4454739.
DOI: 10.1158/1078-0432.CCR-14-0595.
Protein kinase Cδ promotes proliferation and induces malignant transformation in skeletal muscle.
Czifra G, Szollosi A, Nagy Z, Boros M, Juhasz I, Kiss A
J Cell Mol Med. 2014; 19(2):396-407.
PMID: 25283340
PMC: 4407591.
DOI: 10.1111/jcmm.12452.